The increase was primarily driven by strong growth across the Company’s Private segment, which increased by SAR 25.6 million (+38.7%). Growth was supported by new customer onboarding, stronger sell-out rates, targeted trade activation initiatives, and continued expansion across high-value segments such as Specialized Care, Dermatology, and Health & Wellness. Performance was further supported by new product launches, an expanding customer base, and a favorable product mix with increased contribution from pharmaceutical products relative to OTC.

In parallel, Public segment revenues increased by SAR 7.5 million (+28.6%), driven by tender awards, particularly through the National Unified Procurement Company (NUPCO).

Overall growth remained resilient despite geopolitical disruptions, while Export sales reflected a temporary rephasing impact, resulting in a slight decline of SAR 0.3 million (-6.5%) during the quarter.

Improved net profit was driven by strong revenue growth of 33.7% year-on-year, and further supported by stable profitability margins, with net profit margin improving to 20.7% in Q1 2026 from 19.9% in Q1 2025.

The sequential decline mainly reflects seasonal demand normalization in Q1 following a stronger fourth quarter in 2025, when product demand and market activity have historically been higher.

The sequential decline was primarily driven by lower revenue following a seasonally stronger fourth quarter of the previous year.

Net profit was weighed by higher operating expenses, reflecting increased commercial investments during the current quarter, supporting business scalability and positioning the Company for higher market share and increased future revenue generation.